In vitro activities of eight antifungal drugs against 104 environmental and clinical isolates of Aureobasidium pullulans

M Javad Najafzadeh; Deanna A Sutton; M Saradeghi Keisari; H Zarrinfar; G Sybren de Hoog; Anuradha Chowdhary; Jacques F Meis

doi:10.1128/AAC.03095-14

In vitro activities of eight antifungal drugs against 104 environmental and clinical isolates of Aureobasidium pullulans

Antimicrob Agents Chemother. 2014 Sep;58(9):5629-31. doi: 10.1128/AAC.03095-14. Epub 2014 Jul 7.

Authors

M Javad Najafzadeh¹, Deanna A Sutton², M Saradeghi Keisari¹, H Zarrinfar¹, G Sybren de Hoog³, Anuradha Chowdhary⁴, Jacques F Meis⁵

Affiliations

¹ Department of Parasitology and Mycology, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
² University of Texas Health Science Center, San Antonio, Texas, USA.
³ CBS-KNAW Fungal Biodiversity Centre, Utrecht, The Netherlands.
⁴ Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, India.
⁵ Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, The Netherlands j.meis@cwz.nl.

Abstract

Aureobasidium pullulans is an unusual agent of phaeohyphomycosis. The in vitro activities of antifungals against 104 isolates of Aureobasidium pullulans var. pullulans and A. pullulans var. melanigenum revealed low MIC90s of amphotericin B, posaconazole, and itraconazole. However, they were resistant to fluconazole (≥64 μg/ml) and had high MICs of voriconazole, isavuconazole, caspofungin, and micafungin.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antifungal Agents / pharmacology*
Ascomycota / drug effects*
Ascomycota / isolation & purification
Drug Resistance, Fungal
Microbial Sensitivity Tests
Phaeohyphomycosis / drug therapy

Substances

Antifungal Agents